TTR and cancer: The final panel proteins (LRG1, TTR, and CA19-9) were tested on 1002 samples—composed of normal, benign, other cancers, and PDAC—which were divided into training (n=684) and test sets (n=318) at a 4:1 ratio (Supplementary Table 4).